Exclusive Endoscopic Resection of Juvenile Nasopharyngeal Angiofibroma: A Systematic Review of the Literature. (31st December 2013)

• Record Type: Journal Article
• Authors: Khoueir, Nadim; Nicolas, Nicolas; Rohayem, Ziad; Haddad, Amine; Abou Hamad, Walid
• Is Part Of: Otolaryngology--head and neck surgery. Volume 150:Number 3(2014:Mar.)
• Page Start: 350
• Page End: 358
• Publication Date: 2013-12-31
• Subjects: juvenile nasopharyngeal angiofibroma -- endoscopy -- bleeding -- complications -- recurrence; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0194599813516605
• Languages: English
• ISSNs: 0194-5998

Abstract

Abstract : Objective: To systematically review the exclusive endoscopic treatment of juvenile nasopharyngeal angiofibroma in the literature to define the clinical features in terms of staging and the treatment outcomes in terms of bleeding, recurrence, residual tumor, and complications. Data Sources: Online databases, including PubMed and EMBASE, were used. Reference sections of identified studies were examined for additional articles. Review Methods: The literature was searched by 2 reviewers with the following inclusion criteria: English or French language and exclusive endoscopic treatment of juvenile nasopharyngeal angiofibroma. We were only able to perform a meta‐analysis on the categorical outcomes using DerSimonian and Laird random effects models. Results: Ninety‐two studies were included with a majority of retrospective studies (54/92; 58.6%). No randomized controlled trials were found. A total of 821 patients were identified. The Radowski classification was the most commonly used (29/92; 31.15%). The mean operative blood loss was 564.21 mL (minimum, 20 mL; maximum, 1482 mL). It was 414.6 mL (minimum, 20 mL; maximum, 1000 mL) and 774.2 mL (minimum, 228 mL; maximum, 1482 mL), respectively, in the group with and without embolization. No conclusion could be made because it was not stratified by tumor stage and because of the absence of randomized controlled trials. The random effect estimate of recurrence was 10% (95% confidence interval [CI], 8.3‐11.7). It was 9.3% (95% CI, 7.2‐11.5) for complications and 7.7% (95% CI, 5.4‐10.1) for residual tumor. Conclusion: The endoscopic treatment is an evolving modality. It is considered today the treatment of choice. A new classification system based on the endoscopic approach should be proposed in future studies.